1
Cui D#, Wang Y#, Huang L#, Gu X#, Huang Z, Mu S, Wang C*, Cao B*. Rheumatic Symptoms Following Coronavirus Disease 2019 (COVID-19): A Chronic Post-COVID-19 Condition. Open Forum Infect Dis. 2022 May 23;9(6):ofac170. doi: 10.1093/ofid/ofac170.
2
Han X#, Chen L, Li H, Zhou F, Xing X, Zhang C, Suo L, Wang J, Liu X*, Cao B*, CAP-China network. Prognostic Factors for Cardiovascular Events in Elderly Patients with Community Acquired Pneumonia: Results from the CAP-China Network. Clin Interv Aging. 2022 Apr 23;17:603-614. doi: 10.2147/CIA.S356925.
3
Zhuo X#, Zhao J, Wang L, Sun B, Sun L, Wang C, Li B, Fan Y, Liu Y*, Cao B*. Development and evaluation of a multiplex quantitative polymerase chain reaction assay for detecting bacteria associated with lower respiratory tract infection. Int J Infect Dis. 2022 May 26;122:202-211. doi: 10.1016/j.ijid.2022.05.052.
4
Li H#, Zhao M#, Zhang H, Quan C, Zhang D, Liu Y, Liu M, Xue C, Tan S, Guo Y, Zhao Y, Wu G, Gao GF*, Cao B*, Liu WJ*. Pneumonia Severity and Phase Linked to Virus-Specific T Cell Responses with Distinct Immune Checkpoints during pH1N1 Infection.J Immunol. 2022 May 1;208(9):2154-2162. doi: 10.4049/jimmunol.2101021.
5
Xu J#, Cao B*. Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. Eur Respir J. 2022 Jan 6;59(1):2102002. doi: 10.1183/13993003.02002-2021.
6
Gu X#, Cao B*. Understanding of COVID-19 from infection-fatality ratio. Lancet. 2022 Apr 16;399(10334):1442-1443. doi: 10.1016/S0140-6736(22)00281-1.
7
Zhang Y#, Zhao J, Han J, Fan Y, Xiong Z, Zou X, Li B, Liu X, Li Z, Lu B*, Cao B*. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa. Microbiol Spectr. 2022 Apr 27;10(2):e0274021. doi: 10.1128/spectrum.02740-21.
8
Huang L#, Gu X, Zhang H, Cao B*. A glimpse into long COVID and symptoms - Authors' reply. Lancet Respir Med. 2022 Jun 10;S2213-2600(22)00212-0. doi: 10.1016/S2213-2600(22)00212-0.
9
Chang K#, Wang H#, Zhao J, Yang X, Wu B, Sun W, Huang M, Cheng Z, Chen H, Song Y, Chen P, Chen X, Gan X, Ma W, Xing L, Wang Y, Gu X, Zou X, Cao B*.Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii. Front Med (Lausanne). 2022 Jun 10;9:772372. doi: 10.3389/fmed.2022.772372.
10
Zhang X#, Shang L#, Fan G, Gu X, Xu J, Wang Y, Huang L, Cao B*. The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis. Front Med (Lausanne).2022 Jan 27;8:800492. doi: 10.3389/fmed.2021.800492.
11
Huang Z#, Li H, Liu S, Jia J, Zheng Y, Cao B*. Identification of Neutrophil-Related Factor LCN2 for Predicting Severity of Patients With Influenza A Virus and SARS-CoV-2 Infection. Front Microbiol. 2022 Apr 12;13:854172. doi: 10.3389/fmicb.2022.854172.
12
Yu J#, Li H, Jia J, Huang Z, Liu S, Zheng Y, Mu S, Deng X, Zou X, Wang Y, Shang X, Cui D, Huang L, Feng X, Liu W.J, Cao B*. Pandemic influenza A (H1N1) virus causes abortive infection of primary human T cells. Emerg Microbes Infect. 2022 Dec;11(1):1191-1204. doi: 10.1080/22221751.2022.2056523.
13
Huang L#, Li X#, Gu X#, Zhang H#, Ren L#, Guo L#, Liu M#, Wang Y#, Cui D, Wang Y, Zhang X, Shang L, Zhong J, Wang X, Wang J*, Cao B*. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022 May 11;S2213-2600(22)00126-6. doi: 10.1016/S2213-2600(22)00126-6.
15
Zou X#, Suo L#, Wang Y#, Cao H#, Mu S, Wu C, Yan L, Qi X, Lu J, Lu B, Fan Y, Li H, Huang L, Ren L*, Liu B*, Cao B*. Concurrent pigeon paramyxovirus-1 and Acinetobacter baumannii infection in a fatal case of pneumonia. Emerg Microbes Infect. 2022 Dec;11(1):968-977. doi: 10.1080/22221751.2022.2054366.
16
Guo L#, Wang G#, Wang Y#, Zhang Q#, Ren L#, Gu X#, Huang T, Zhong J, Wang Y, Wang X, Huang L, Xu L, Wang C, Chen L, Xiao X, Peng Y, Julian C Knight, Dong T, Cao B*, Wang J*.SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe. 2022 Mar 23. doi: 10.1016/S2666-5247(22)00036-2.
